AI Stock Monitor
JNJ - Johnson & Johnson
Johnson & Johnson is a North America covered company in The Hedge Book research universe.
Public company · North America · Healthcare · Pharmaceuticals · Medical Devices · Dow constituent
0 followers · Follow to include this stock in your daily 9:30 AM Central watchlist email.
NYSE · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score
60
/100
Price History
JNJ chart
AI-Assisted Chart Analysis
Johnson & Johnson technical analysis
Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.
Constructive uptrend: the latest level is above the 50-period average and the 50-period average is above the 200-period average.
RSI is 65, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.
The first technical watch zone is 247.02. A break below 222.89 invalidates the near-term support setup.
The first resistance/watch zone is 266.73. A confirmed break above 267.24 supports continuation.
Annualized realized volatility is +18.4%. Maximum lookback drawdown is -11.0%, from a high-water mark of 248.56 to 221.32.
Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.
How To Read This Stock Brief
Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.
Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.
Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.
This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.
What Changed Today
- Yahoo Finance delayed market data reported JNJ at 259.92 USD; the latest daily move rose +0.26%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.
Why It Matters
- The verified +0.26% daily move is current market context for Johnson & Johnson.
- It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
- Those require a separately sourced filing or company update.
AI Opinion
- Read: The current evidence-grounded AI read is bullish.
- Evidence: The $5.5 billion talc settlement is a material positive, as it removes a persistent cloud of litigation risk that has historically weighed on valuation multiples.
- Uncertainty: The entry into surgical robotics via OTTAVA is a key long-term catalyst, though its impact on revenue and margins will likely be gradual as the company builds its installed base.
- Watch: The retirement of a key pharmaceutical leader introduces execution risk, and investors will be looking for continuity in the company's drug pipeline and commercial strategy under new leadership.
Key Risks
- The $5.5 billion settlement, while resolving a major issue, represents a substantial cash outflow that could impact capital allocation priorities or balance sheet flexibility in the near term.
- Leadership transitions in the pharmaceutical division could lead to temporary operational friction or strategic shifts that may disrupt the momentum of key drug franchises.
- The surgical robotics market is highly competitive, and JNJ faces significant hurdles in gaining market share against entrenched incumbents with large installed bases.
- Regulatory or pricing pressures in the pharmaceutical sector remain a persistent risk that could impact margins, regardless of the company's internal progress.
Upcoming Catalysts
- Successful commercial rollout and market adoption of the OTTAVA robotic surgical system would serve as a primary indicator of long-term growth in the MedTech segment.
- Future earnings calls and investor conferences, such as the upcoming Wells Fargo Healthcare Conference, will provide opportunities for management to clarify the strategic direction under new leadership.
- Continued strong performance in the oncology portfolio, particularly with key drugs like Darzalex, remains essential to offsetting potential patent cliffs and maintaining revenue growth.
- Any further updates regarding the finalization and payment schedule of the talc settlement will be closely monitored for its impact on cash flow and balance sheet health.
Upcoming Events
No verified update available
Last Updated
Sources and verification
Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.
- Published stock briefSecondary sourceAnalyst OpinionJohnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually. - The Motley Fool · Published 2026-08-10 09:04:27Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedDownload JNJ03 Data | Johnson & Johnson TDR Price Data - marketwatch.com · Published 2026-08-10 09:04:27Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedJohnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually. - Yahoo Finance · Published 2026-08-10 09:04:27Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedJohnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually. · Published 2026-08-10 09:04:27Open verification sourceSupports: Published stock brief
- Published stock briefSecondary sourceReportedHow Much Do You Need Invested by 50 to Retire on Dividends at 60? · Published 2026-08-10 09:04:27Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.
Community View
Sign in with Google to vote once per stock.
Total votes: 0
Disclaimer
The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.